乳腺癌 z-bo 2020-10-23 319

　　Recently, a new study led by Flinders University found a link between beta blockers and the survival outcomes of certain breast cancer patients.

　　According to a new paper in "Frontiers In Oncology", β-blockers commonly used to treat cardiovascular diseases are inversely related to the survival outcomes of HER2-positive advanced breast cancer patients.

　　Using data collected from a clinical trial conducted in 2777 patients, the study showed that patients in the HER2-positive ABC group with β-blockers had better survival outcomes than patients who did not use β-blockers difference.

　　Flinders University School of Medicine and School of Public Health Precision Medicine Professor Michael Sorich (Michael Sorich) said: "This study highlights that a group of breast cancer patients have significantly poorer survival outcomes."

　　"Given that about 20% of breast cancer patients overexpress HER2, and cardiovascular toxicity is a known complication of anti-HER2 therapy, this study has importantly identified a subgroup of patients. We recommend further research to find improved treatment results. Strategy."

　　This study concluded: "Future research should aim to gain a deeper understanding of the effects of β-blockers on specific breast cancer subtypes, cancer types and cancer treatments."